Target intelligence / Profile preview

Proteasome 20S core particle (20S proteasome)

Target
20S proteasome
Molecular classification
Enzyme, Protease complex, Multi-catalytic protease, Other (Proteolytic core of the proteasome complex)
01

Overview

The proteasome 20S core particle is a highly conserved, cylindrical, multi-subunit protease complex at the center of the cellular protein degradation machinery in eukaryotes[1][2][3][4][6]. It consists of four stacked heptameric rings arranged in an α_7–β_7–β_7–α_7 configuration, creating a central proteolytic chamber where protein substrates are degraded into short peptides[1][2][3][4]. The two outer α rings form gated entry points that control substrate access, while the two inner β rings contain the proteolytic active sites. Three β subunits (β1, β2, β5) confer caspase-like, trypsin-like, and chymotrypsin-like activities, respectively[1][6][4]. The 20S core particle can act independently or as part of the larger 26S proteasome complex when capped with regulatory particles that recognize ubiquitinated substrates[2][5]. Through its central role in regulated protein degradation, the 20S proteasome core is essential for cellular homeostasis, quality control, immune surveillance (via antigen processing), cell cycle regulation, and stress responses. Inhibition of the 20S core's activity is a validated therapeutic strategy for various cancers—notably multiple myeloma—and the core is overactive or dysfunctional in many diseases involving abnormal protein homeostasis[5][6][8].

Other names
20S proteasome20S core particle20S CP20S core complex
02

Mechanism of action

Inhibition of proteolytic activity, leading to accumulation of polyubiquitinated proteins and induction of apoptosis in cancer cells[5][6]. Disruption of protein homeostasis and cell cycle arrest

03

Biological functions

Protein degradationCell cycle regulationApoptosisImmune response (antigen processing)Protein quality controlCellular homeostasis
04

Disease associations

CancerNeurodegenerative diseaseInfectionInflammationOther (protein misfolding disorders)
05

Safety considerations

Peripheral neuropathy (notably with bortezomib)Hematologic toxicities (thrombocytopenia, neutropenia)Gastrointestinal effects (nausea, diarrhea)Increased infection riskDevelopment of resistance in tumor cells
06

Interacting drugs

Bortezomib

5 more in the full profile.

07

Biomarkers

Elevated proteasome activity in blood or tissues (as in multiple myeloma, lymphoma)Levels of polyubiquitinated proteins as a readout of proteasome inhibition

Beyond the preview

Go deeper on Proteasome 20S core particle (20S proteasome).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Proteasome 20S core particle (20S proteasome).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call